Ramucirumab
- Generic Name
- Ramucirumab
- Brand Names
- Cyramza
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 947687-13-0
- Unique Ingredient Identifier
- D99YVK4L0X
- Background
Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and down...
- Indication
Ramucirumab is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel for patients who progress after prior fluoropyrimidine- or platinum-containing chemotherapy. It is indicated, in combination with erlotinib, for the first-line treatment of metastatic no...
- Associated Conditions
- Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Non-Small Cell Lung Cancer, Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
- Associated Therapies
- -
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
- Conditions
- Interventions
- First Posted Date
- 2017-09-13
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 410
- Registration Number
- NCT03281369
- Locations
- 🇺🇸
Uni of Southern California; Norris Comprehensive Cancer Ctr, Los Angeles, California, United States
🇺🇸Tennessee Oncology - Nashville, Nashville, Tennessee, United States
🇦🇺Peter MacCallum Cancer Centre; Medical Oncology, Melbourne, Victoria, Australia
Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2020-07-20
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03193918
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT03141034
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸H. Lee Moffitt Cancer Center and Research Institute, Inc., Tampa, Florida, United States
Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients with Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy
- Conditions
- Interventions
- First Posted Date
- 2017-03-16
- Last Posted Date
- 2024-12-12
- Target Recruit Count
- 429
- Registration Number
- NCT03081143
- Locations
- 🇦🇹
Ordensklinikum Linz GmbH, Barmherzige Schwestern, Linz, Upper Austria, Austria
🇦🇹Landeskrankenhaus Feldkirch - Rankweil, Rankweil, Vorarlberg, Austria
🇦🇹Wiener Neustadt, Landesklinikum, Wiener Neustadt, Austria
Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery
- Conditions
- Recurrent Gastroesophageal Junction AdenocarcinomaStage III Esophageal Cancer AJCC v7Metastatic Gastric CarcinomaRecurrent Esophageal CarcinomaStage III Gastric Cancer AJCC v7Stage IV Esophageal Cancer AJCC v7Metastatic Esophageal CarcinomaMetastatic Gastroesophageal Junction AdenocarcinomaUnresectable Esophageal CarcinomaUnresectable Gastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2017-01-02
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT03008278
- Locations
- 🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope Upland, Upland, California, United States
Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-11-22
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Athenex, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02970539
- Locations
- 🇺🇸
CTRC-UT, San Antonio, Texas, United States
🇨🇳Lotung Poh-Ai Hospital, Yilan, Taiwan
🇨🇳Tri-Service General Hospital, Taipei, Taiwan
Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers
- Conditions
- Interventions
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2021-09-13
- Target Recruit Count
- 280
- Registration Number
- NCT02934464
- Locations
- 🇮🇹
Maria Di Bartolomeo, Milan, Italy
A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-06-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 440
- Registration Number
- NCT02898077
- Locations
- 🇲🇾
University Malaya Medical Centre, Kuala Lumpur, Malaysia
🇲🇾National Cancer Institute, Wilayah Persekutuan, Malaysia
🇹🇭Rajavithi Hospital, Bangkok, Ratchathewi District, Thailand
A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-07-13
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Eli Lilly and Company
- Registration Number
- NCT02831491
A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
- Conditions
- Interventions
- First Posted Date
- 2016-06-10
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 43
- Registration Number
- NCT02795858
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.